About Jupiter Endovascular
Jupiter Endovascular is a company based in Menlo Park (United States) founded in 2024.. Jupiter Endovascular has raised $61 million across 2 funding rounds from investors including Senvest Capital, LB Investment and Sonder Capital. Jupiter Endovascular offers products and services including Endoportal Control and Vertex Pulmonary Embolectomy System. Jupiter Endovascular operates in a competitive market with competitors including Instylla, Spectrum Vascular, Access Point Technologies, Ridgeback Technologies and SlipStream Medical, among others.
- Headquarter Menlo Park, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$61 M (USD)
in 2 rounds
-
Latest Funding Round
$40 M (USD), Series B
Oct 07, 2025
-
Investors
Senvest Capital
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Jupiter Endovascular
Jupiter Endovascular offers a comprehensive portfolio of products and services, including Endoportal Control and Vertex Pulmonary Embolectomy System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Technology merging surgical precision with catheter interventions for treatments.
System for treating pulmonary embolism through controlled endovascular procedures.
Unlock access to complete
Unlock access to complete
Funding Insights of Jupiter Endovascular
Jupiter Endovascular has successfully raised a total of $61M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $40 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $40.0M
-
First Round
First Round
(15 Aug 2024)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series B - Jupiter Endovascular | Valuation | Sonder Capital | |
| Aug, 2024 | Amount | Series B - Jupiter Endovascular | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Jupiter Endovascular
Jupiter Endovascular has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Senvest Capital, LB Investment and Sonder Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage medtech startups are invested in by Sonder Capital.
|
Founded Year | Domain | Location | |
|
Multiple sectors are invested in by this private equity firm.
|
Founded Year | Domain | Location | |
|
Growth-stage private equity investments are targeted across multiple sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Jupiter Endovascular
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Jupiter Endovascular
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Jupiter Endovascular Comparisons
Competitors of Jupiter Endovascular
Jupiter Endovascular operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Instylla, Spectrum Vascular, Access Point Technologies, Ridgeback Technologies and SlipStream Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Hydrogel technology is developed for embolization therapy applications.
|
|
| domain | founded_year | HQ Location |
Vascular access medical devices are developed by Spectrum Vascular.
|
|
| domain | founded_year | HQ Location |
A range of EP diagnostic and ablation catheters is developed.
|
|
| domain | founded_year | HQ Location |
Catheter balloons are developed with short lead times.
|
|
| domain | founded_year | HQ Location |
Manufacturer of catheter insertion device
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Jupiter Endovascular
Frequently Asked Questions about Jupiter Endovascular
When was Jupiter Endovascular founded?
Jupiter Endovascular was founded in 2024.
Where is Jupiter Endovascular located?
Jupiter Endovascular is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Who is the current CEO of Jupiter Endovascular?
Carl St Bernard is the current CEO of Jupiter Endovascular.
Is Jupiter Endovascular a funded company?
Jupiter Endovascular is a funded company, having raised a total of $61M across 2 funding rounds to date. The company's 1st funding round was a Series B of $21M, raised on Aug 15, 2024.
What does Jupiter Endovascular do?
Jupiter Endovascular was founded in 2024 and is based in Menlo Park, United States. Focus is placed on the development of minimally invasive medical devices within the endovascular intervention sector. The endoportal procedure is being advanced as a novel approach to endovascular interventions, incorporating Endoportal Control for improved precision and control in catheter-based methods. Operations center on innovation in device technology for vascular applications.
Who are the top competitors of Jupiter Endovascular?
Jupiter Endovascular's top competitors include Instylla, Spectrum Vascular and Ridgeback Technologies.
What products or services does Jupiter Endovascular offer?
Jupiter Endovascular offers Endoportal Control and Vertex Pulmonary Embolectomy System.
Who are Jupiter Endovascular's investors?
Jupiter Endovascular has 3 investors. Key investors include Senvest Capital, LB Investment, and Sonder Capital.